Ezlopitant (INN,[1] code name CJ-11,974) is an NK1 receptor antagonist.

[2][3][4] It has antiemetic and antinociceptive effects.

[5][6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.

This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.